GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medivir AB (OSTO:MVIR) » Definitions » Cyclically Adjusted PB Ratio

Medivir AB (OSTO:MVIR) Cyclically Adjusted PB Ratio : 0.11 (As of May. 29, 2025)


View and export this data going back to 1996. Start your Free Trial

What is Medivir AB Cyclically Adjusted PB Ratio?

As of today (2025-05-29), Medivir AB's current share price is kr1.778. Medivir AB's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 was kr15.55. Medivir AB's Cyclically Adjusted PB Ratio for today is 0.11.

The historical rank and industry rank for Medivir AB's Cyclically Adjusted PB Ratio or its related term are showing as below:

OSTO:MVIR' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.08   Med: 0.36   Max: 2.89
Current: 0.11

During the past years, Medivir AB's highest Cyclically Adjusted PB Ratio was 2.89. The lowest was 0.08. And the median was 0.36.

OSTO:MVIR's Cyclically Adjusted PB Ratio is ranked better than
87.46% of 670 companies
in the Biotechnology industry
Industry Median: 1.485 vs OSTO:MVIR: 0.11

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Medivir AB's adjusted book value per share data for the three months ended in Mar. 2025 was kr0.915. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is kr15.55 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


Medivir AB Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Medivir AB's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medivir AB Cyclically Adjusted PB Ratio Chart

Medivir AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.24 0.42 0.36 0.14 0.17

Medivir AB Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.14 0.16 0.16 0.17 0.08

Competitive Comparison of Medivir AB's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Medivir AB's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medivir AB's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Medivir AB's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Medivir AB's Cyclically Adjusted PB Ratio falls into.


;
;

Medivir AB Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Medivir AB's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=1.778/15.55
=0.11

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medivir AB's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Medivir AB's adjusted Book Value per Share data for the three months ended in Mar. 2025 was:

Adj_Book=Book Value per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=0.915/132.8245*132.8245
=0.915

Current CPI (Mar. 2025) = 132.8245.

Medivir AB Quarterly Data

Book Value per Share CPI Adj_Book
201506 37.944 99.995 50.401
201509 37.701 100.228 49.962
201512 36.622 100.276 48.509
201603 35.786 100.751 47.178
201606 34.786 101.019 45.738
201609 33.264 101.138 43.686
201612 43.631 102.022 56.804
201703 26.391 102.022 34.359
201706 23.281 102.752 30.095
201709 20.611 103.279 26.507
201712 17.160 103.793 21.960
201803 16.239 103.962 20.747
201806 13.677 104.875 17.322
201809 11.702 105.679 14.708
201812 8.524 105.912 10.690
201903 6.975 105.886 8.749
201906 6.631 106.742 8.251
201909 5.996 107.214 7.428
201912 5.111 107.766 6.299
202003 4.461 106.563 5.560
202006 4.105 107.498 5.072
202009 4.235 107.635 5.226
202012 3.932 108.296 4.823
202103 4.923 108.360 6.034
202106 4.670 108.928 5.695
202109 4.482 110.338 5.395
202112 4.134 112.486 4.881
202203 3.652 114.825 4.224
202206 3.312 118.384 3.716
202209 3.095 122.296 3.361
202212 2.834 126.365 2.979
202303 2.557 127.042 2.673
202306 2.170 129.407 2.227
202309 1.827 130.224 1.863
202312 2.085 131.912 2.099
202403 1.888 132.205 1.897
202406 1.569 132.716 1.570
202409 1.264 132.304 1.269
202412 1.030 132.987 1.029
202503 0.915 132.825 0.915

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Medivir AB  (OSTO:MVIR) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Medivir AB Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Medivir AB's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Medivir AB Business Description

Industry
Traded in Other Exchanges
Address
Lunastigen 5, PO Box 1086, 2nd floor, Huddinge, SWE, 141 22
Medivir AB develops drugs with a focus on cancer, where unmet medical needs are high. The company is concentrating on the development of fostroxacitabine bralpamide (fostrox), a liver-targeted inhibitor of DNA replication that selectively delivers the cell-killing agent to the tumor while minimizing potentially harmful effects on normal cells. It has developed two pharmaceutical products: Xerclear, used for treating labial herpes (cold sores), and Olysio, which have reached the market. Medivir also has various out-licensed projects, such as MIV-701, birinapant, USP-1/TNG348, USP-7, and MBLI/MET-X, as well as two other drug projects, remetinostat and MIV-711, in the clinical development phase. Geographically, it generates its maximum revenue from Europe and other regions.

Medivir AB Headlines

No Headlines